8 results about "Cell signaling pathways" patented technology

The invention discloses a liver tissue regeneration regulation and control method based on epigenetic state regulation and control, and relates to the technical field of biology. Comprising the following steps: sampling the liver tissue at a plurality of preset time points after the liver tissue is damaged or partially resected, selecting a target gene related to liver tissue regeneration regulation, and detecting an epigenetic state of a promoter region of the target gene; comparing and analyzing the change of the epigenetic state of the target gene promoter region on the basis of detection results obtained at different time points, and determining epigenetic modification characteristics in the liver tissue regeneration process; according to an analysis result, intervening the expression level of a regulatory factor related to DNA methylation or DNA hydroxymethylation so as to regulate the epigenetic state of the target gene promoter region; after intervention is completed, the transcription expression condition of a target gene and the activity change of a cell signal channel related to liver tissue regeneration are detected, and the liver tissue regeneration process can be effectively regulated and controlled through the method.

The application discloses a detection kit based on a colorimetric method and application thereof, and the detection kit comprises two membrane protein recognition chains T1 and T2, two DNA hairpins H1 and H2 required for forming G-quadruplex, hematin required for a color developing reaction, hydrogen peroxide (H2O2) and ABTS. The membrane protein recognition chains T1 and T2 can anchor membrane proteins, and adjacent hybridization occurs when the membrane proteins dimerize, thereby triggering catalytic hairpin self-assembly of H1 and H2 to form a large number of G-quadruplex structures; when H2O2 exists, G-quadruplex / hematin formed by combining G-quadruplex and hematin can catalyze oxidation of ABTS to generate a color developing reaction. The detection kit has the characteristics of high sensitivity, good specificity, low cost, low dependence on equipment and simple operation in the detection of cell membrane protein dimerization, and also has good application performance in cell signal pathway visualization and rapid diagnosis of tumor cells at a bedside.

The invention belongs to the technical field of biological medicines, and particularly relates to application of neratinib in preparation of a medicine for preventing and treating noise-induced deafness. According to the specific technical scheme, the application of the neratinib in preparation of the medicine for preventing and treating hearing impairment / deafness is provided. According to the invention, the fact that neratinib can play a hearing protection role by specifically regulating and controlling cochlea immune microenvironment is found for the first time, and the hearing protection role is specifically realized by the following mechanisms: regulating and controlling biological effects such as cell signal channels, inflammatory response and cell stress response, protecting hair cell structures, and reducing cochlea basilar membrane outer hair cell loss caused by noise exposure. Based on the new discovery of the invention, the neratinib can be used for preparing medicines for preventing and treating hearing impairment and deafness caused by noise.

The invention discloses a method for improving proliferation and activity of cytokine-induced killer cells, and belongs to the technical field of cellular immunity. According to the method, the human peripheral blood mononuclear cells are firstly cultured in the culture medium containing the cell factors, then the obtained CIK cells are cultured in the culture medium containing the cell factors and the PP2A inhibitor, the amplification efficiency of the CIK cells is improved through the PP2A inhibitor, and the proportion of CD3 + CD56 + cells in the CIK cells is increased; according to the invention, a cell signal transduction pathway regulator PP2A inhibitor is ingeniously introduced, and culture conditions are optimized, so that the amplification efficiency of CIK cells is remarkably improved, and the proportion of functional subgroups is improved. Meanwhile, on the basis of improving the cell performance, the preparation cost of the CIK cell is relatively reduced, and the CIK cell is particularly suitable for preparing a CIK cell preparation required by adoptive immunotherapy and can be widely applied to treatment of solid tumors and blood system tumors.

The invention relates to a single cell signal road reconstruction method, system and device and a medium. The method comprises the following steps: extracting a sub-network from a global signal reference network based on an intersection of a highly expressed gene and a hypervariable gene of each cell, and generating a cell specific signal network; inputting the cell specificity signal network into a Transform model to generate a consensus signal network; defining the consensus signal network corresponding to the source cell as a source cell consensus network, and defining the consensus signal network corresponding to the target cell as a target cell consensus network; and on the basis of a ligand-receptor knowledge base, searching a path between a ligand in the source cell consensus network and a receptor in the target cell consensus network, and generating a cross-cell signal path list. By adopting the method, the intercellular communication mechanism can be accurately captured, and the systematic understanding of intercellular signals is effectively improved.

The present invention relates to immune cells overexpressing externally introduced cell signaling pathway modulators and uses thereof. As a specific example, immune cells expressing a fusion protein comprising a chimeric antigen receptor and a cell signaling pathway modulator perform an immune response by selecting target cancer cells through the chimeric antigen receptor expressed on the cell membrane. In this case, the cell signaling pathway modulator is overexpressed in the cytoplasm, thereby being able to modulate the activity of the immune cells. Accordingly, the fusion protein comprising a chimeric antigen receptor and a cell signaling pathway modulator of the present invention, and the immune cells overexpressing the cell signaling pathway modulator can be used for the treatment of cancer.

The application provides a 1-heteroaryl-3-sulfone group bicyclo[1.1.1]pentane compound and a preparation method and application thereof, and belongs to the technical field of synthesis of pharmaceutical intermediates. The compound provided by the application is a double-substituted bicyclo[1.1.1]pentane containing a sulfone group and a heteroaryl group and derivatives thereof, wherein the sulfone group is an important pharmacophore, plays a role in antitumor drugs by participating in hydrogen bond interaction, regulating cell signaling pathways and the like, and the series of compounds have antitumor activity. The application uses cheap and easily available sulfonic acid chlorides, [1.1.1]spiro propeller and heteroaromatic compounds as raw materials, and prepares a series of sulfone group and heteroaryl group double-substituted bicyclo[1.1.1]pentane under mild conditions through a three-component tandem reaction with high selectivity and high yield, and the preparation method is simple and suitable for industrial production.

Methods and compositions for treating a subject suffering from adrenocortical carcinoma and having excess cortisol are disclosed. The methods provide therapeutic benefits including reduction of ACC tumor load, restoration of T-cell and natural killer (NK) cell signaling pathways, increase in T-cell and NK cell infiltration into the ACC tumor, reduction of neutrophil infiltration into the ACC tumor in the patient, and other therapeutic benefits. The methods include administration of a glucocorticoid receptor modulator (GRM) (which may be a selective glucocorticoid receptor modulator (SGRM)) and an antibody checkpoint inhibitor. In embodiments, the GRM (e.g., a SGRM) is orally administered. The GRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.